GSK Said To Consider Ending China Business If Huge Fine Levied
This article was originally published in PharmAsia News
Executive Summary
Citing "serious concerns" over its future in China, a source said GlaxoSmithKline may end its operations in the country if the government follows through on threats of a fine as high as the $3 billion the U.S. ordered the firm to pay last year.